Asked by: Baroness Merron (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what progress they have made in reducing inequalities in outcomes for breast cancer patients from black and minority ethnic backgrounds over the past (1) 10 years, (2) five years, and (3) two years.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Reducing inequalities and improving breast cancer outcomes for ethnic minority women is a priority for the Government. To support this work, NHS England has commissioned six new cancer clinical audits, which will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments, and help stimulate improvements in cancer treatments and outcomes for patients, including for breast cancer. The Royal College of Surgeons began work on this audit in October 2022, and the first outcomes are expected in September 2024.
NHS England is also leading a programme of work to tackle healthcare inequalities centred around five clear priorities, which are set out in the operational planning guidance for the health system. The Core20PLUS5 approach proactively targets groups that are less likely to engage with services in the most deprived quintile of the population, along with ethnic minority communities and inclusion health groups, across five clinical areas which includes early cancer diagnosis, specifically screening and early referral.
The issue of improving equality monitoring, by reference to ethnicity and the other eight protected characteristics, is being considered at a national level under the programme called the Unified Information Standard for Protected Characteristics (UISPC). Evaluating the use of the 2021 ethnicity census categories is part of this programme. The UISPC Publication Steering Group is reporting to NHS England and the Department this year, which will inform a view on the next steps, including any plans for publication and consultation, and an implementation timetable. Preparatory work has been undertaken by NHS England that would facilitate the introduction of the 2021 ethnicity codes, should a decision be made to adopt the 2021 ethnicity census codes, or to implement an alternative approach to ethnicity, if recommended.
NHS England’s operational planning guidance recognises the importance of improving the quality of data for patient characteristics. This is one of the five strategic priorities in their drive to reduce healthcare inequalities, as improved data quality will help to reveal health inequalities and inform action to address them. NHS England has therefore asked systems to continue to improve the collection and recording of ethnicity data across primary care, outpatients, accident and emergency, mental health, community services, and specialised commissioning.
NHS England’s National Disease Registration Service (NDRS) collects ethnicity data for all cancer patients through a variety of routine, national data feeds, including the Cancer Outcomes and Services Dataset, Hospital Episode Statistics data, and Patient Administration System data. The NDRS publishes key performance indicator data on the national registration statistics for England. The latest published indicator data, for invasive cancer cases excluding non-melanoma skin cancers, diagnosed in 2020, shows that ethnicity data is complete for 94.9% of cases.
Asked by: Baroness Merron (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they are taking to improve the collection and reporting of ethnicity data for breast cancer patients to support understanding of variations in outcomes and patient experience of NHS care.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Reducing inequalities and improving breast cancer outcomes for ethnic minority women is a priority for the Government. To support this work, NHS England has commissioned six new cancer clinical audits, which will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments, and help stimulate improvements in cancer treatments and outcomes for patients, including for breast cancer. The Royal College of Surgeons began work on this audit in October 2022, and the first outcomes are expected in September 2024.
NHS England is also leading a programme of work to tackle healthcare inequalities centred around five clear priorities, which are set out in the operational planning guidance for the health system. The Core20PLUS5 approach proactively targets groups that are less likely to engage with services in the most deprived quintile of the population, along with ethnic minority communities and inclusion health groups, across five clinical areas which includes early cancer diagnosis, specifically screening and early referral.
The issue of improving equality monitoring, by reference to ethnicity and the other eight protected characteristics, is being considered at a national level under the programme called the Unified Information Standard for Protected Characteristics (UISPC). Evaluating the use of the 2021 ethnicity census categories is part of this programme. The UISPC Publication Steering Group is reporting to NHS England and the Department this year, which will inform a view on the next steps, including any plans for publication and consultation, and an implementation timetable. Preparatory work has been undertaken by NHS England that would facilitate the introduction of the 2021 ethnicity codes, should a decision be made to adopt the 2021 ethnicity census codes, or to implement an alternative approach to ethnicity, if recommended.
NHS England’s operational planning guidance recognises the importance of improving the quality of data for patient characteristics. This is one of the five strategic priorities in their drive to reduce healthcare inequalities, as improved data quality will help to reveal health inequalities and inform action to address them. NHS England has therefore asked systems to continue to improve the collection and recording of ethnicity data across primary care, outpatients, accident and emergency, mental health, community services, and specialised commissioning.
NHS England’s National Disease Registration Service (NDRS) collects ethnicity data for all cancer patients through a variety of routine, national data feeds, including the Cancer Outcomes and Services Dataset, Hospital Episode Statistics data, and Patient Administration System data. The NDRS publishes key performance indicator data on the national registration statistics for England. The latest published indicator data, for invasive cancer cases excluding non-melanoma skin cancers, diagnosed in 2020, shows that ethnicity data is complete for 94.9% of cases.
Asked by: Lord Kempsell (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government how many people diagnosed with cancer underwent a needs assessment and were given a personalised care and support plan in (1) 2021, (2) 2022, and (3) 2023.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The information is not available, as the data is not collected in the format requested.
Asked by: Lord Kempsell (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government how many people who completed cancer treatment were offered an 'end of treatment summary' in (1) 2021, (2) 2022, and (3) 2023.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The information is not available, as the data is not collected in the format requested.
Asked by: Lord Warner (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the impact of the NHS England uniform pricing policy on patients' access to innovative medicines.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England has successfully secured patient access to a number of innovative medicines under its policy of uniform pricing. European industry data from April 2023 showed that for every four treatments available in Europe, there is an additional medicine available in England, and a quarter more cancer drugs available in England compared to the European average.
Asked by: Lord Warner (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government how many commercial agreements NHS England has made with manufacturers of medicines which allow, support or result in non-uniform pricing by individual medicine.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Since April 2020, NHS England has agreed to 37 commercial agreements that have resulted in non-uniform pricing by medicine, via either the Cancer Drugs Fund, or through bespoke commercial deals to support routine commissioning.
Asked by: Daisy Cooper (Liberal Democrat - St Albans)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the press notice entitled Major agreement to deliver new cancer vaccine trials, published on 5 July 2023, whether brain cancer patients will be given access to the treatments and therapies made available through that programme.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Government’s partnership with BioNTech aims to provide up to 10,000 United Kingdom patients with personalised immunotherapies by 2030. As well as cancer vaccines, BioNTech has several other classes of cancer therapy under development, such as engineered cell therapies and antibodies. We are not able to comment at this stage on the exact pipeline of clinical trials that BioNTech will go on to launch in the UK, over the coming years.
Asked by: Fleur Anderson (Labour - Putney)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential merits of offering breast cancer screening to women going through early menopause.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The UK National Screening Committee (UK NSC) currently recommends that all women aged 50 to 71 years old are invited for a breast screening every three years. The AgeX trial is looking at the impact of increasing or decreasing the screening age for breast screening, and the UK NSC will review its findings when they are available.
The UK NSC can be alerted to any new published peer reviewed evidence which may suggest the case for a new screening programme, or changes to an existing one. Proposals can be submitted via the UK NSC’s annual call in July 2024, which is available at the following link:
Asked by: Theresa Villiers (Conservative - Chipping Barnet)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much funding her Department has allocated to pancreatic cancer research in each of the last five years.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Research is crucial in tackling cancer, which is why the Department invests £1.3 billion per year in health research through the National Institute for Health and Care Research (NIHR). The NIHR's research expenditure for all cancers was £121.8 million in 2022/23, and the NIHR spends more on cancer than any other disease group.
The NIHR funded nine research projects on pancreatic cancer since 2018/19, with a committed funding value of £4.3 million.
The following table shows NIHR spending on pancreatic cancer research for the period April 2018 to March 2023, based on contracted funding over this period, correct as of 29 April 2024:
Year commenced | Pancreatic cancer research awards actual spending |
2018/19 | £545,000 |
2019/20 | £525,000 |
2020/21 | £348,000 |
2021/22 | £145,000 |
2022/23 | £735,000 |
Total | £2.3 million |
In addition, NIHR Biomedical Research Centres and NIHR Clinical Research Facilities spent a further £6.5 million between 2018/19 and 2022/23 supporting an annual portfolio of around 85 early clinical studies in pancreatic cancer.
The NIHR also supports delivery in the health and care system of research into pancreatic cancer, funded by research funding partners in the charity and public sectors. Since 2018/19 the NIHR supported 73 clinical research studies through the Clinical Research Network.
The NIHR funds research in response to proposals received from scientists rather than allocating funding to specific disease areas. The NIHR welcomes funding applications for research into any aspect of human health, including pancreatic cancer. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.
Asked by: Lord Bourne of Aberystwyth (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what data they collected on other countries that have restricted smoking when drafting the Tobacco and Vapes Bill.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Smoking is responsible for approximately 80,000 deaths a year in the United Kingdom and causes around one in four UK cancer deaths. It also costs society £21.8 billion a year and puts a huge burden on the National Health Service. The latest estimates from Action on Smoking and Health put the cost of smoking to the NHS and social care at £3 billion a year.
As part of our impact assessment, we reviewed evidence and data from a range of countries. This included modelling from New Zealand, Singapore, and the Solomon Islands on the estimated impact of a smokefree generation policy on smoking prevalence, smoking attributable mortality, and other health impacts. We also considered evidence and data from countries that have already implemented an increase in the age of sale for tobacco to a particular age. For example, we analysed data and evidence from the United States on the impact that raising the age of sale from 18 to 21 years old had on smoking prevalence.
This was in addition to considering evidence and data from the UK on the impact that previous increases in the age of sale for tobacco have had on smoking prevalence. A copy of our Tobacco and Vapes Bill - impact assessment is attached.